Journal of Pharmaceutical Investigation

The Korean Society of Pharmaceutical Sciences and Technology (한국약제학회)
권호 표지
DOI QR코드

DOI QR Code

Preparation and Characterization of Plasmid DNA Encapsulated in Liposomes

플라스미드 유전자를 함유한 리포좀의 제조 및 특성

  • 박효민 (이화여자대학교 약학대학) ;
  • 정수연 (이화여자대학교 약학대학) ;
  • 고은정 (이화여자대학교 약학대학) ;
  • 이화정 (이화여자대학교 약학대학)
  • Published : 2003.09.20
Download PDF
⟨ Previous Next ⟩

Abstract

The objective of this study was to construct the pegylated liposomes containing plasmid DNA with optimal encapsulation efficiency. Plasmid DNA $(pGL2\;clone\;753,\;{\sim}6\;kb)$ was encapsulated by the freeze/thawing method into liposomes composed of 1-palmitoyl-2-oleyl-sn-glycerol-3-phosphocholine (POPC), didodecyl dimethyl ammonium bromide (DDAB), distearoylphosphatidyl ethanolamine polyethylene glycol 2000 (DSPE-PEG 2000) and DSPE-PEG 2000-male-imide. The liposomes containing plasmid DNA were then extruded through two stacked polycarbonate filters with series of different pore sizes to control the liposome size. The plasmid DNA entrapped in the liposomes was separated from free plasmid DNA by Sephadex CL-4B column chromatography. The decreased pore size of polycarbonate filters resulted in the decreased size of liposomes. The encapsulation efficiency was markedly affected by the cationic lipid (DDAB) concentration, but to a low degree by the size of liposomes and by the amount of plasmid DNA.

Keywords

References

  1. E. Galanis, R. Vile and S.J. Russell, Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors, Crit. Rev. Oncol. Hematol.,38, 177-192 (2001) https://doi.org/10.1016/S1040-8428(01)00103-2
  2. A.D. Miller, Retroviral vectors, Curr. Top. Microbial. Immunol., 158, 1-24 (1992) https://doi.org/10.1007/978-3-642-75608-5_1
  3. T.A. Smith, M.G. Mehaffey, D.B. Kayda, J.M. Saunders, S. Yei, B.C. Trapnell, A . McClelland and M. Kaleko, Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice, Nature Genet., 5, 397-402 (1993) https://doi.org/10.1038/ng1293-397
  4. Y. Setoguchi, H.A. Jaffe, C.-S. Chu and R.G. Crystal, Intraperitoneal in vivo gene therapy to deliver alpha 1-antitrypsin to the systemic circulation, Am. J. Resp. Cell Mol. BioI., 10, 369-377 (1994) https://doi.org/10.1165/ajrcmb.10.4.8136153
  5. Y. Yang, F.A. Nunes, K. Berencsi, E.E. Furth, E. Gonczol and J.M. Wilson, Cellular immunity to viral antigens limits El-deleted adenoviruses for gene therapy, Proc. Natl. Acad. Sci. USA, 91, 4407-4411 (1995)
  6. Y. Yang, Q. Li, H.C.J. Erte and J.M. Wilson, Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses, J. Virol., 69, 2004-2015 (1995)
  7. D.H. Hamer and P. Leder, Splicing and the formation of stable RNA, Cell, 18, 1299-1302 (1979) https://doi.org/10.1016/0092-8674(79)90240-X
  8. R.C. Mulligan, B.H. Howard and P. Berg, Synthesis of rabbit beta-globin in cultured monkey kidney cells following infection with a SV40 beta-globin recombinant genome, Nature (London), 277, 108-114 (1979) https://doi.org/10.1038/277108a0
  9. S. Li and L. Huang, Nonviral gene therapy: promises and challenges, Gene Ther., 7, 31-34 (2000) https://doi.org/10.1038/sj.gt.3301110
  10. A.G. Schatzlein, Non-viral vectors in cancer gene therapy: principles and progress, Anti-Cancer Drugs, 12, 275-304 (2001) https://doi.org/10.1097/00001813-200104000-00001
  11. J. Smith, Y. Zhang and R. Niven, Toward development of a non-viral gene therapeutic, Adv. Drug Deliv. Rev., 26, 135-150 (1997) https://doi.org/10.1016/S0169-409X(97)00031-8
  12. N. Shi and W.M. Pardridge, Noninvasive gene targeting to the brain, Proc. Natl. Acad. Sci. USA, 97, 7567-7572 (2000) https://doi.org/10.1073/pnas.130187497
  13. J. Huwyler, W. Dafang and W.M. Pardridge, Brain drug delivery of small molecules using immunoliposomes, Proc. Natl. Acad. Sci. USA, 93, 14164-14169 (1996) https://doi.org/10.1073/pnas.93.24.14164
  14. P-A. Monnard, T. Oberholzer and P.L. Luisi, Entrapment of nucleic acids in liposomes, Biochim. Biophys. Acta, 1329, 39-50 (1997) https://doi.org/10.1016/S0005-2736(97)00066-7
  15. E.G. Sarabolac, O. Ludkovski, R. Skirrow, M. Ossanlou, Y.P. Zhang, C. Giebrecht, J. Thompson, S. Thomas, H. Stark, P.R. Cullis and P. Scherrer, Encapsulation of plasmid DNA in stabilized plasmid-lipid particles composed of different cationic lipid concentration for optimal transfection activity, J. Drug Target., 7, 423-437 (2000) https://doi.org/10.3109/10611860009102217
  16. K.J. Harrington, E. Linardakis and R.G. Vile, Transcriptional control: an essential component of cancer gene therapy strategies, Adv. Drug Deliv. Rev., 44, 167-184 (2000) https://doi.org/10.1016/S0169-409X(00)00093-4
  17. S. Akhtar, M.D. Hughes, A. Khan, M. Bibby, M. Hussain, Q. Nawaz, J. Double and P. Sayyed, The delivery of antisense therapeutics, Adv. Drug Deliv. Rev., 44, 3-21 (2000) https://doi.org/10.1016/S0169-409X(00)00080-6
  18. S. Akhtar and S. Agrawal, In vivo studies with antisense oligonucleotides, Trends Pharmacal. Sci., 18, 12-18 (1997) https://doi.org/10.1016/S0165-6147(96)01002-4
  19. E.R. Kandimalla and S. Agrawal, Antisense Therapeutics: is it as simple as complementary base recognition, Mol. Med. Today, 6, 72-81 (2000) https://doi.org/10.1016/S1357-4310(99)01638-X
  20. M. Sioud, Application of preformed hammerhead ribozymes in gene therapy of cancer, Int. J. Mol. Med., 3, 381-384 (1999)
  21. D. Sen and C.R. Geyer, DNA enzymes, Curr. Opin. Chem. BioI., 2, 680-687 (1998) https://doi.org/10.1016/S1367-5931(98)80103-8